WEBULL
WebtradeDownload

Sundrug (TSE:9989) Stock Holds Ground As Margins Tighten

Simply Wall St · 1d ago

The stock price closed Q1 earnings day near ¥3,746 after a flat week and a soft month, yet SundrugLtd quietly posted a cleaner story than the share chart suggests. Basic earnings per share in Q1 came in around ¥68.5 with net income of about ¥8.0b on revenue of roughly ¥215.3b. The market has been fixated on a modest squeeze in net profit margin to 3.7% over the last year. The current issue is whether that pressure is already in the price or if investors are only starting to price it in.

Love SundrugLtd's solid revenue base but concerned about that squeeze in net profit margin? Check out our list of solid balance sheet and fundamentals stocks (40 results).

Q1 2027 Earnings Summary

  • Revenue, Q1 2027 vs Q1 2026: ¥215,331m vs. ¥207,698m (steady year on year growth)
  • Net Income, Q1 2027 vs Q1 2026: ¥8,017m vs. ¥7,944m (broadly stable profit level)
  • Basic EPS, Q1 2027 vs Q1 2026: ¥68.53 vs. ¥67.92 (marginal improvement per share)
  • Net Profit Margin, Trailing 12 Months vs Prior Year: 3.7% vs. 3.9% (slight margin compression on recent results)

Prefer clean charts instead of another wall of earnings tables and ratios? See SundrugLtd's full financial picture, with an easy-to-scan view of its recent earnings and broader financials, in our company report for SundrugLtd.

TSE:9989 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TSE:9989 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Sundrug revenue resilience supports defensive thesis

The latest quarter keeps Sundrug looking like a steady, defensive retailer. Revenue of ¥215.3b and net income of ¥8.0b are broadly in line with the prior year, and basic EPS nudged higher. That fits a story of everyday demand holding up across drugstore and discount formats. Margins sit at 3.7% on a trailing basis, which is not aggressive but is still positive. For investors who see Sundrug as a staple driven, lower volatility exposure, these numbers point to a business that is holding its ground rather than stalling.

Margin compression keeps competition risk in focus

The slight squeeze in trailing net profit margin from 3.9% to 3.7% backs up concerns about competitive pressure in Japanese drugstores. Profit is stable in yen terms, yet the business is giving up a little profitability per sales yen. Short term share performance is also subdued, with the stock roughly flat over 90 days and down about 3% over 30 days. That kind of muted price action fits a cautious view that Sundrug must work harder on efficiency or mix to avoid further erosion in already modest margins.

Track how SundrugLtd's steady revenue, modest margin pressure and recent share price reaction stack up against institutional expectations. Then check whether analysts see this as a stock holding its ground or losing steam with the consensus price target analysis for SundrugLtd.

Take Control Of Your Next Move

If SundrugLtd's steady revenue and recent margin pressure have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. After you own SundrugLtd or any other stock, keep your decisions clear with the Portfolio Command Center that focuses you on key events rather than day to day noise. For a broader view on what other investors are seeing, use the Community to tap into different perspectives and questions around SundrugLtd. This combination helps surface potential catalysts and risks early so you can act with confidence and stay ahead of the market.

Seeking Alternatives Beyond SundrugLtd Now

Fresh ideas often move first, and latecomers get caught chasing momentum after prices are already flying. Scan under the radar for now, before the crowd, and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.